Curebase and Adaptive Biotechnologies Collab to Expand Study Access
Curebase and Adaptive Biotechnologies Corp. have announced an ongoing research collaboration to broaden patient participation in Adaptive’s clinical studies. The initial two studies of the partnership involve Adaptive’s T-Detect diagnostic test. T-Detect is under development for multiple diseases translating the natural diagnostics capability of T-Cells into clinical practice.
The first study will validate the effectiveness of T-Detect for patients with Lyme disease. Lyme disease tends to impact people in rural areas, where a lack of clinical research sites makes it more challenging to recruit participants for clinical studies. In a second study, the two companies will collect and analyze long-term data from COVID-19 patients who have used Adaptive’s T-Detect COVID clinically available test.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
CAHtalyst Trial Shows Crenessity Sustains Efficacy in Classic Congenital Adrenal Hyperplasia
July 14th 2025Results from the Phase III CAHtalyst show that patients treated with Crenessity for classic congenital adrenal hyperplasia achieved and maintained lower, more physiologic glucocorticoid doses while keeping key adrenal biomarkers at or below baseline levels.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
